The Care Ledger

Daily edition Saturday, November 7, 2026

Search
Tuesday, November 17, 2026Today's Paper From the publisher Free hospital price search Published bysoro
The Care Ledger

Daily edition

Saturday, November 7, 2026

Everything The Care Ledger published that day: 1 story, the news in brief and the figures.

  • 01

    Lilly's obesity drugs go on sale through Hims & Hers.

    Zepbound, the injectable, starts at $299 a month and Foundayo, Lilly's daily pill, at $149 a month for self-pay patients, the same cash prices Lilly offers any patient, according to the companies' announcement on Friday. Hims & Hers has committed not to sell compounded copies of Lilly's drugs.

    Hims & Hers

  • 02

    Most brand-generic patent settlements now delay the generic

    Of 2,405 settlements reported to the Federal Trade Commission for fiscal 2004 through 2021, 86% restricted when the generic could launch, a share that rose from 36% in 2004 to 95% in 2021, a Harvard team reported in JAMA Health Forum on Friday.

    JAMA Health Forum

  • 03

    KFF reruns its 340B math on the final rule

    With Medicare paying hospitals average sales price minus 28% for 340B drugs from January 1, 2027, KFF estimates safety-net hospitals lose 5.2% of outpatient revenue while for-profit hospitals gain 6.8%, because the cut is offset by a 7.5% increase in payments for non-drug outpatient services.

    KFF

  • 04

    Four states sue over the Medicaid work requirement

    Oregon, joined by Minnesota, New Mexico and Washington, filed suit in federal court in Oregon on Thursday challenging the constitutionality of the work requirement that takes effect January 1, 2027, STAT reported. Oregon's Department of Justice says the rule would require more than half a million Oregonians to file regular paperwork to keep coverage.

    STAT, Oregon DOJ

  1. 8%to 9%

    Humana's expected core medical cost growth for 2027, up from 7% to 8% for 2026

    Humana priced its 2027 Medicare Advantage plans for margin as costs rise 8% to 9%

  2. 14%to 15%

    expected growth in Humana's Part D drug costs in 2027, priced into its bids

    Humana priced its 2027 Medicare Advantage plans for margin as costs rise 8% to 9%

  3. 93.7%

    share of premiums Humana's insurance segment spent on care in the third quarter, against guidance of slightly above 94%

    Humana priced its 2027 Medicare Advantage plans for margin as costs rise 8% to 9%

  4. 1,208,000

    individual Medicare Advantage members Humana added this year through September, a 23% increase

    Humana priced its 2027 Medicare Advantage plans for margin as costs rise 8% to 9%